Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

500
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
500
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

117
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
117
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

229
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
229
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

173
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
173
Imaging Studies for Cardiovascular System I:Echocardiography01:17

Imaging Studies for Cardiovascular System I:Echocardiography

624
Cardiac imaging studies encompass a wide range of noninvasive and minimally invasive techniques designed to visualize the heart's structure and function in detail. One such technique is echocardiography, which uses high-frequency ultrasound waves to produce detailed images of the heart, known as echocardiograms.
Indications: Echocardiography is utilized to diagnose heart failure, valve disorders, and myocardial infarction. It also assesses cardiac structures' size, shape, and motion,...
624
Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

2.5K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
2.5K
このページは機械翻訳されています。他のページは英語で表示される場合があります。View in English
  1. ホーム
  2. 研究分野
  3. 生物医学と臨床科学
  4. 心血管医学と血液学
  5. 心臓病 (心血管疾患を含む)
  6. 低エジェクション分数 (untouched) の患者におけるs-icdによる第1次予防試験の理解結果

低エジェクション分数 (UNTOUCHED) の患者におけるS-ICDによる第1次予防試験の理解結果

Michael R Gold1, Pier D Lambiase2, Mikhael F El-Chami3

  • 1Department of Medicine, Medical University of South Carolina, Charleston (M.R.G.).

Circulation
|October 19, 2020

関連する実験動画

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System
10:17

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

Published on: April 11, 2025

1.4K
Primary Outcome Assessment in a Pig Model of Acute Myocardial Infarction
14:19

Primary Outcome Assessment in a Pig Model of Acute Myocardial Infarction

Published on: October 14, 2016

11.9K
A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation
16:40

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation

Published on: February 28, 2012

26.6K

PubMed で要約を見る

まとめ
この要約は機械生成です。

S-ICDは心不全の予防に安全で有効です. 高リスクの患者におけるS- ICDの現在の使用は,低不適切なショック率を示し,安全性と有効性の改善を示しています.

科学分野:

  • 心臓病科
  • 電気生理学
  • 医療機器

背景:

  • 皮下埋め込み式心動除細動器 (S-ICD) は,突然の心臓死亡の予防に使用されます.
  • 以前のS- ICD研究では,併発症と左心室機能不全が少ない患者が含まれていました.
  • 経静脈 ICD 試験と比較して,以前の S- ICD 試験では不適切なショック率 (IAS) が高かった.

研究 の 目的:

  • 現代のS-ICD患者集団における不適切なショック率 (IAS) を評価する.
  • S- ICDの安全性と有効性を評価する.
  • MADIT-RIT研究から得られた業績目標とIAS率を比較する.

主な方法:

  • UNTOUCHED試験には,左心室排出分数 ≤35%のプライマリ予防患者が含まれていました.
  • 第2世代または第3世代S-ICDデバイスは,特定の速度および形態学的差別基準で埋め込まれ,プログラムされました.
  • 患者は18ヶ月間追跡され,IASフリー率のプライマリエンドポイントを評価した.

主要な成果:

  • 18ヶ月間IASからの免除は95.9%で,業績目標を超えました.
  • 18ヶ月の全原因無ショック率は90.6%で 既定の目標を達成しました
キーワード:
心臓発作インプラント式除細動器心不全主要予防について

関連する実験動画

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System
10:17

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

Published on: April 11, 2025

1.4K
Primary Outcome Assessment in a Pig Model of Acute Myocardial Infarction
14:19

Primary Outcome Assessment in a Pig Model of Acute Myocardial Infarction

Published on: October 14, 2016

11.9K
A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation
16:40

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation

Published on: February 28, 2012

26.6K
  • 18ヶ月の合併症のない割合は92. 7%で,適切なショックでの成功率は98. 4%でした.
  • 結論:

    • 現代のS-ICDデバイスとプログラミングは,高併発性患者集団において高い有効性と安全性を実証しています.
    • 観察された不適切なショック率は,S- ICDで報告された中で最も低く,静脈経 ICD研究と好意的に比較されます.
    • S-ICDは,現代の患者の突然心臓死予防のための安全で効果的な選択肢です.
    心臓発作による突然死
    静脈動脈症 静脈動脈症
    静脈動脈不全 静脈動脈不全